VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemesMarketEarningsCompareWatchlistInsider
AZTAAzenta, Inc.
$23.31$1.1B
Research
Overview
Valuation
ValuationTargetsPrice
Financials
RevenueEarningsP/ERatiosDividend
Ownership
Holders
Tools
Total ReturnDCA Calculator
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

Follow VCP Scanner on XFollow VCP Scanner on LinkedIn
© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksAZTAP/E History

AZTA logoAzenta, Inc. (AZTA) P/E Ratio History

Deep Value

Trading at -19.1x · 0th percentile of 5-year range · Significant discount to historical valuation · Data 1997–2022

Current P/E (TTM)
-19.1x
-144% vs 5Y avg
5Y Avg P/E
43.9x
Median 52.6x
5Y Percentile
0th
Lower end of range
PEG Ratio
N/A
5-Year P/E Range
-19.1x
Min5.0xMedian52.6xMax109.5x
TTM EPS$-3.87
Price$23.31
Earnings YieldN/A
EPS Growth (1Y)60.5%
EPS Growth (5Y)N/A

Loading P/E history...

P/E Ratio Analysis

As of June 22, 2026, Azenta, Inc. (AZTA) trades at a price-to-earnings ratio of -19.1x, with a stock price of $23.31 and trailing twelve-month earnings per share of $-3.87.

The current P/E is 144% below its 5-year average of 43.9x. Over the past five years, AZTA's P/E has ranged from a low of 5.0x to a high of 109.5x, placing the current valuation at the 0th percentile of its historical range.

Compared to the Healthcare sector median P/E of 22.1x, AZTA trades at a 186% discount to its sector peers. The sector includes 234 companies with P/E ratios ranging from 0.0x to 197.0x.

Relative to the broader market, AZTA trades at a notable discount to the S&P 500 median P/E of 24.4x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.

For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our AZTA DCF Valuation Calculator →

Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.

AZTA Cross-Benchmark Valuation

How does the current P/E compare to sector peers and the broader market?

vs. Healthcare
-19.1vs22.1
-186%
Below Sector
vs. S&P 500
-19.1vs24.4
-178%
Below Market
PEG Analysis
N/A
P/E ÷ EPS Growth
Based on 61% EPS growth (1Y)

AZTA P/E vs Peers

Diagnostics and life science tools peers sorted by market cap

CompanyMarket CapP/E RatioPEG RatioEPS Growth (1Y)
ITRN logoITRNIturan Location and Control Ltd.
$1B22.40.73+8%
CCSI logoCCSIConsensus Cloud Solutions, Inc.
$628M7.8Lowest--6%
QGEN logoQGENQiagen N.V.
$8B18.10.40Best+437%Best
TMO logoTMOThermo Fisher Scientific Inc.
$173B26.212.40+7%
DHR logoDHRDanaher Corporation
$125B35.2--5%

Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.

AZTA Historical P/E Data (1997–2022)

Quarterly P/E ratios calculated from closing price and TTM EPS

QuarterPeriod EndPriceTTM EPSP/E Ratiovs Avg
FY2022 Q4Sep 30 2022$42.86$0.39109.5x+31%
FY2022 Q3-$72.10$0.7595.8x+14%
FY2022 Q2-$82.88$1.3860.2x-28%
FY2022 Q1Dec 31 2021$103.11$1.7259.9x-28%
FY2021 Q4-$102.35$1.4968.7x-18%
FY2021 Q3Jun 30 2021$95.28$1.5959.9x-28%
FY2021 Q2Mar 31 2021$81.65$1.2565.3x-22%
FY2021 Q1-$67.85$1.0564.6x-23%
FY2020 Q4Sep 30 2020$46.26$0.8852.6x-37%
FY2020 Q3-$44.24$6.187.2x-91%
FY2020 Q2-$30.50$6.095.0x-94%
FY2020 Q1-$41.96$6.027.0x-92%
FY2019 Q4Sep 30 2019$37.03$6.046.1x-93%
FY2019 Q3Jun 30 2019$38.75$0.5077.5x-8%
FY2019 Q2Mar 31 2019$29.33$0.7240.7x-51%
FY2019 Q1Dec 31 2018$26.18$1.6216.2x-81%
FY2018 Q4Sep 30 2018$35.03$1.6521.2x-75%
FY2018 Q3Jun 30 2018$32.62$1.7518.6x-78%
FY2018 Q2Mar 31 2018$27.08$1.6816.1x-81%
FY2018 Q1Dec 31 2017$23.85$0.9325.6x-69%
FY2017 Q4Sep 30 2017$30.36$0.9033.7x-60%
FY2017 Q3Jun 30 2017$21.69$0.8027.1x-68%
FY2017 Q2Mar 31 2017$22.40$0.6733.4x-60%
FY2016 Q1-$10.68$0.1858.7x-30%
FY2015 Q4Sep 30 2015$11.71$0.2155.9x-33%
FY2015 Q3-$11.45$0.11101.3x+21%
FY2015 Q2-$11.63$0.3632.0x-62%
FY2015 Q1Dec 31 2014$12.75$0.3734.2x-59%
FY2014 Q4-$10.51$0.4622.7x-73%
FY2014 Q3Jun 30 2014$10.77$0.5519.6x-77%
FY2014 Q2Mar 31 2014$10.93$0.2152.0x-38%
FY2014 Q1-$10.49$0.1569.1x-18%
FY2013 Q3Jun 30 2013$9.73$1.645.9x-93%
FY2013 Q2Mar 31 2013$10.18$1.745.8x-93%
FY2013 Q1Dec 31 2012$8.05$1.904.2x-95%
FY2012 Q4Sep 30 2012$8.04$2.083.9x-95%
FY2012 Q3Jun 30 2012$9.44$0.5018.9x-77%
FY2012 Q2Mar 31 2012$12.33$1.418.7x-90%
FY2012 Q1Dec 31 2011$10.27$1.676.1x-93%
FY2011 Q4Sep 30 2011$8.15$1.994.1x-95%
FY2011 Q3-$10.86$2.175.0x-94%
FY2011 Q2-$13.73$1.409.8x-88%
FY2011 Q1Dec 31 2010$9.07$1.326.9x-92%
FY2010 Q4-$6.71$0.927.3x-91%
FY2010 Q3Jun 30 2010$7.73$0.3224.5x-71%
FY2008 Q2Mar 31 2008$9.72$0.1280.5x-4%
FY2008 Q1Dec 31 2007$13.21$1.697.8x-91%
FY2007 Q4Sep 30 2007$14.24$2.017.1x-92%
FY2007 Q3Jun 30 2007$18.15$2.248.1x-90%
FY2007 Q2Mar 31 2007$17.15$2.177.9x-91%
FY2007 Q1Dec 31 2006$14.40$0.8018.0x-79%
FY2006 Q4Sep 30 2006$13.05$0.3339.5x-53%
FY2005 Q3-$14.85$0.12118.9x+42%
FY2005 Q2-$15.18$0.3740.5x-52%
FY2005 Q1Dec 31 2004$17.22$0.5730.2x-64%
FY2004 Q4-$14.15$0.3639.3x-53%
FY2001 Q3Jun 30 2001$46.10$0.4896.0x+15%
FY2001 Q2Mar 31 2001$39.75$0.5967.4x-20%
FY2001 Q1Dec 31 2000$28.06$0.8433.4x-60%
FY2000 Q4Sep 30 2000$33.13$0.7643.6x-48%
FY1998 Q1Dec 31 1997$18.38$0.011717.3x+1949%
FY1997 Q4-$38.38$0.031279.2x+1426%
FY1997 Q3Jun 30 1997$19.25$0.12160.4x+91%
FY1997 Q2Mar 31 1997$14.88$0.3839.1x-53%

Average P/E for displayed period: 83.8x

Export Data
Consensus-Based Analysis Tools

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

29+ years return with dividends reinvested.

Calculate

DCA Calculator

See how regular investing compounds over time.

Run Numbers

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

AZTA — Frequently Asked Questions

Quick answers to the most common questions about buying AZTA stock.

What is AZTA's P/E ratio?

Azenta, Inc. (AZTA) trailing twelve-month P/E ratio is -19.1x, based on TTM diluted EPS of $-3.87. The 5-year average P/E is 43.9x and the historical range spans 5.0x to 109.5x.

Is AZTA stock overvalued or undervalued?

AZTA trades at -19.1x P/E, below its 5-year average of 43.9x. At the 0th percentile of its historical range (5.0x–109.5x), the stock is priced at a discount to its own history.

Is AZTA stock expensive?

No, AZTA is not expensive on a historical basis. The current P/E of -19.1x is below the 5-year average of 43.9x and sits at the 0th percentile of its valuation range.

What is AZTA's historical P/E range?

Over the past 5 years, AZTA's P/E ratio has ranged from 5.0x to 109.5x, with a median of 52.6x and an average of 43.9x. The current P/E of -19.1x places the stock at the 0th percentile of this range. Full historical data spans 1997–2022.

How does AZTA's P/E compare to the S&P 500?

AZTA trades at -19.1x P/E versus the S&P 500 median of 24.4x. The 178% discount to the market suggests lower growth expectations or perceived higher risk.

How does AZTA's valuation compare to Healthcare peers?

Azenta, Inc. P/E of -19.1x compares to the Healthcare sector median of 22.1x. The discount suggests lower growth expectations, weaker margins, or higher perceived risk relative to peers. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.

What is AZTA's PEG ratio?

AZTA PEG ratio is N/A, based on a P/E of -19.1x and EPS growth of 60.5%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.

What is AZTA's earnings yield?

AZTA earnings yield is N/A, the inverse of its -19.1x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.

AZTA P/E Ratio History (1997–2022)

Quarterly valuation multiple from closing price and trailing EPS

Current109.5x
Period Avg43.9x
Range5.0x - 109.5x
Change+327%
20 quartersDec 31, 2017 - Sep 30, 2022